Trial Profile
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms RETHINC
- 07 Nov 2021 Status changed from active, no longer recruiting to completed.
- 30 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Sep 2021.
- 30 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Sep 2021.